By Drug Class / Mechanism

Small Molecule Oral Agents (Kinase Inhibitors, Antifibrotics) Market Analysis

Cross-industry research covering Small Molecule Oral Agents (Kinase Inhibitors, Antifibrotics) across 1 market reportspanning Pharmaceuticals & Medical Devices — Ophthalmic Surgery.

1 Reports

1 Industries

Reports Covering Small Molecule Oral Agents (Kinase Inhibitors, Antifibrotics)

Oculoplastic Surgery Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR

Pharmaceuticals & Medical Devices — Ophthalmic Surgery·Market: USD 4.8 Billion (2025)·CAGR: 7.2%

A nascent but high-optionality class, led by linsitinib (Sling Therapeutics, NCT05276063) in TED and 5-fluorouracil as an adjuvant in DCR procedures (NCT07154121). A successful linsitinib NDA would create the first oral prescription drug indication in oculoplastic disease, opening a retail pharmacy channel entirely absent from today's market.

10%

Market Share

22.1%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments